Published On: Sun, Nov 23rd, 2014

Universal flu vaccine co BiondVax mulls NY IPO

BiondVax is exploring two options – either a conventional offering or listing American Depositary Receipts.

Biondvax-vaccine3

 

Universal flu vaccine developer BiondVax Pharmaceuticals Ltd. (TASE:BNDX) is mulling a Wall Street IPO, sources inform “Globes.” The company has a market cap of NIS 42 million on the Tel Aviv Stock Exchange (TASE).

BiondVax is exploring two options either a conventional offering or listing American Depositary Receipts (ADR) for trading. The company will be required to file a prospectus with the US Securities and Exchange Commission (SEC) and the bookrunner is likely to be Aegis. The company value is likely to be close to its present market cap in Tel Aviv. After trading on the market for a while the company may try for a higher value.

Biondvax’s universal flu vaccine has already undergone a successful Phase II trial (efficacy study) and has received approval for a Phase II clinical trial in Israel, which will take place in 2015.

The company lose NIS 4.1 million in the first half of 2014 and has no revenue, and cash reserves of NIS 14.1 million. Biondvax was founded by its CEO Ron Babecoff.

 

Published by Globes [online], Israel business news – www.globes-online.com

Read more about: , , , , , , , , , , , , , , , , , , ,

Wordpress site Developed by Fixing WordPress Problems